{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-open-label-multicenter-clinical-study-to-evaluate-the-safety-and-efficacy-of-mk-1084-cetuximab-and-mfolfox6-versus-mfolfox6-with-or-without-bevacizumab-as-first-line-treatmen\/#breadcrumbitem"}]}